SynthesisNuclear medicine communications2021
Reassessment of the lung dose limits for radioembolization.
Synthesis in Nuclear medicine communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Glass versus resin microspheres in ⁹⁰Y radioembolization for hepatocellular carcinoma: toxicity patterns under uniform voxel-based dosimetry.Annals of nuclear medicine · 2026Article
- From probability to practice: demystifying when lung shunt fraction matters inRadiology advances · 2026Article
- When is patient-specific lung shunt fraction necessary inRadiology advances · 2026Article
- Q.Liver software for the planning of treatment of liver cancer via transarterial radioembolization with yttrium-90 resin microspheres based on single-photon emission computed tomography-computed tomography.Quantitative imaging in medicine and surgery · 2026Article
- Research trends of selective internal radiation therapy for liver cancer: a bibliometric analysis.Radiation oncology (London, England) · 2025Review
- Lung shunting and radiation pneumonitis after holmium-166 TARE: a case study.EJNMMI reports · 2025Article
- Addressing lung truncation inEJNMMI physics · 2024Article
- Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Seminars in interventional radiology · 2024Review
- Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.European journal of radiology open · 2023Article
- Factors modulatingJournal of applied clinical medical physics · 2022Article
- Lung Dose Measured on PostradioembolizationJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioembolization, also known as selective internal radiation therapy (SIRT), is an established treatment for the management of patients with unresectable liver tumors. Advances in liver dosimetry and new knowledge about tumor dose-response relationships have helped promote the well-tolerated use of higher prescribed doses, consequently transitioning radioembolization from palliative to curative therapy. Lung dosimetry, unfortunately, has not seen the same advances in dose calculation methodology and renewed consensus in dose limits as normal liver and tumor dosimetry. Therefore, the efficacy of curative radioembolization may be compromised in patients where the current lung dose calculations unnecessarily limit the administered activity. The field is thus at a stage where a systematic review and update of lung dose limits is necessary to advance the clinical practice of radioembolization. This work summarizes the historical context and literature for origins of the current lung dose limits following radioembolization, that is, the 25-year-old, single institution, small patient cohort series that helped establish the lung shunt fraction and dose limits. Newer clinical evidence based on larger patient cohorts that challenges the historical data on lung dose limits are then discussed. We conclude by revisiting the rationale for current lung dose limits and by proposing a staged approach to advance the field of lung dosimetry and thus the practice of radioembolization as a whole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.